search
Back to results

Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination

Primary Purpose

Liver Fibrosis

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Research FibroScan
Sponsored by
Echosens
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Liver Fibrosis focused on measuring FibroScan, Vibration Control Transient Elastography, Vibration Guided Transient Elastography, Liver Stiffness Measurement, VCTE, VGTE

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adult and pediatric patients, all etiologies combined
  • Patient must be able to give written informed consent, or the parents in the case of a minor patient
  • Patient affiliated to a social security system

Exclusion Criteria:

  • Vulnerable patient- other than pediatric patients
  • Pregnant or breastfeeding woman

Sites / Locations

  • CHU d'Amiens
  • CHU d'Angers
  • CHU de Lille
  • Hôpital Saint Eloi
  • CHU de Nancy
  • CHU de Nice

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Adults and pediatric patients, all etiologies combined

Arm Description

Outcomes

Primary Outcome Measures

Validity criteria of the Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE) (automatically assessed by the Reference and the Research FibroScan)
The validity criteria is an analysis of the measurement, automatically computed by the FibroScan. A measurement analyzed as "valid" leads to a reliable LSM whereas a measurement analyzed as "invalid" leads to a non-reliable LSM.

Secondary Outcome Measures

The bias between the CAPc measured with the VCTE (Reference FibroScan) and the CAPc measured by the Vibration Guided Transient Elastography (VGTE) (Research FibroScan).
Calculate the bias between the PCD measured by the VCTE (Reference FibroScan) and the PCD measured by the VGTE (Research FibroScan).

Full Information

First Posted
February 5, 2021
Last Updated
October 12, 2021
Sponsor
Echosens
search

1. Study Identification

Unique Protocol Identification Number
NCT04747457
Brief Title
Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination
Official Title
Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
April 6, 2021 (Actual)
Primary Completion Date
September 29, 2021 (Actual)
Study Completion Date
September 29, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Echosens

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an European, prospective, interventional, and multicenter exploratory clinical investigation that will take place in 6 French sites and 200 patients will be included (adults and children). The study objective is to develop predictive indicators of homogeneous propagation of ultrasound and elastic waves to define an optimal region of interest for the measurement of liver stiffness during VCTE examination.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Fibrosis
Keywords
FibroScan, Vibration Control Transient Elastography, Vibration Guided Transient Elastography, Liver Stiffness Measurement, VCTE, VGTE

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Adults and pediatric patients, all etiologies combined
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Research FibroScan
Intervention Description
After having obtained the patient's Informed Consent Form signature, the following 3 examinations will be done: Standard examination [Reference CE-marked FibroScan]: the operator will need to find an optimal measurement area, and perform 10 valid measurements. Standard examination [Research FibroScan]: the operator must take 15 valid measurements at the same measurement point as the one used for the examination with the Reference FibroScan. Exploratory examination [Research FibroScan]: the operator needs to perform15 invalid measurements to acquire data in non-optimal regions of measurement (lungs, vessels, intestines, ribs, edges of the liver).
Primary Outcome Measure Information:
Title
Validity criteria of the Liver Stiffness Measurement (LSM) by Vibration Controlled Transient Elastography (VCTE) (automatically assessed by the Reference and the Research FibroScan)
Description
The validity criteria is an analysis of the measurement, automatically computed by the FibroScan. A measurement analyzed as "valid" leads to a reliable LSM whereas a measurement analyzed as "invalid" leads to a non-reliable LSM.
Time Frame
7 months
Secondary Outcome Measure Information:
Title
The bias between the CAPc measured with the VCTE (Reference FibroScan) and the CAPc measured by the Vibration Guided Transient Elastography (VGTE) (Research FibroScan).
Time Frame
7 months
Title
Calculate the bias between the PCD measured by the VCTE (Reference FibroScan) and the PCD measured by the VGTE (Research FibroScan).
Time Frame
7 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult and pediatric patients, all etiologies combined Patient must be able to give written informed consent, or the parents in the case of a minor patient Patient affiliated to a social security system Exclusion Criteria: Vulnerable patient- other than pediatric patients Pregnant or breastfeeding woman
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jérôme Boursier, Pr
Organizational Affiliation
University Hospital, Angers
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU d'Amiens
City
Amiens
Country
France
Facility Name
CHU d'Angers
City
Angers
Country
France
Facility Name
CHU de Lille
City
Lille
Country
France
Facility Name
Hôpital Saint Eloi
City
Montpellier
Country
France
Facility Name
CHU de Nancy
City
Nancy
Country
France
Facility Name
CHU de Nice
City
Nice
Country
France

12. IPD Sharing Statement

Learn more about this trial

Development of Predictive Indicators of Homogeneous Propagation of Ultrasound and Elastic Waves During VCTE Examination

We'll reach out to this number within 24 hrs